Project Reports & Profiles » Best Business Opportunities in Mauritius, Africa - Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

Best Business Opportunities in Mauritius, Africa - Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

Why should start a business in Mauritius

Mauritius, with a population of 1.2 million people, is one of Africa's developed countries. People of Mauritius are recognised for their friendliness and tolerance. It is ranked top in the African area out of 47 countries. It attracts a large number of tourists due to its beautiful beaches. Mauritius' economy is a mixed developing economy based on exports, agriculture, financial services, and tourism.

Agriculture continues to play a significant role in Mauritius' economy, even as the island's manufacturing sector grows and the island becomes a more popular tourist destination. Consequently Despite the fact that it welcomes all investors, Mauritius is one country that defies the trend. The tiny island nation is usually cited as an example of Africa's success. Getting closer to developing economies necessitates Also, look into the advantages of the type of business you choose. The government has compiled a list of the types of businesses you can create in Mauritius to help you make an informed selection. Mauritius' economic growth, as measured by the average annual rate of GDP growth, has been steady in recent years. It boasts one of the most open and efficient business environments in the region. The value of goods and services exported and imported accounts for 94.9 percent of GDP. Mauritius offers a skilled population and a diverse range of low-risk firms that can yield substantial profits. Mauritius' prosperity stems mostly from its stable government, begin a business Mauritius is a great place to establish a business. Textiles, food processing, apparel, chemicals, metal products, transportation equipment, tourism, and non-electrical machinery are all major businesses

What are the natural resources in Mauritius

Mauritius' land is one of the country's most valuable natural resources. Minerals are among of Mauritius' most important natural resources, according to the economy. One of the most valuable natural resources is natural beauty. Sugarcane, bananas, and corn are among the principal crops farmed in Mauritius. The Ministry of Agro-Industry and Food Security was established by the Mauritius government to oversee the agricultural sector. Mauritius' forests are one of the most important natural resources, aside from the agricultural area inside its borders. According to estimates, woods cover over 20% of Mauritius' total land area, and the country's forested acreage has decreased considerably. Several measures have been taken to mitigate the effects of fast deforestation. In Mauritian woods, exotic trees such as eucalyptus, beefwood, Moreton Bay pine, and Japanese cedar were introduced. Mauritius is a one-of-a-kind African country in that it is forced to import wood products due to high demand.

What are the business opportunities in Mauritius?

Agriculture, tourism, real estate, and exports are the first three. Mauritius is a small island nation where the majority of goods are imported from all over the world. As a result, delivery services are always in high demand.

(2) Deliver larger products in order to make a profit. Everything you'll need for

this business possibility

(3)Oil and oil-based products are employed in a variety of industries, including transportation and industry. As a result, such products will always be in demand, making it a solid investment option. You can make a lot of money if you can import these products and repackage them into smaller cans.

(4) Restaurant or any food trade in an economy dominated by tourists. You can start with a food cart, which does not require a lot of money. Make sure your menu is diverse enough to appeal to everyone, especially foreigners who might enjoy a taste of their native country's cuisine now and then. Develop your brand, and when you're ready, a restaurant might be a good fit.

Mauritius is the

(5) fifth country on the list. Medical equipment

Manufacturing of high-end medical gadgets is a lucrative possibility in Mauritius because it is a world-renowned tourist destination and people visit this lovely country even for medical tourism.

What businesses are successful in Mauritius

Mauritius has seen an infusion of foreign firms and economic progress in recent years. Restaurants and hotels, as well as the building industry, are booming. Costa Cruises has announced that its first cruise ship will be built in Port Louis. While the economy has been improving, there are still lots of prospects for foreigners who wish to start their own company. Construction, hospitality, education, and medical services are among the businesses where foreigners can operate with little competition. If you're thinking about launching a business in Mauritius, you should know that tourism is one of the country's most important businesses. It draws over 1.2 million tourists each year, providing a significant source of revenue for people employed in restaurants, hotels, tour companies, real estate offices, and other businesses. more. You may get started with relatively little capital if you have experience as a hotel manager or sales representative at a luxury resort, or if you can offer premium tourism activities like diving tours or helicopter rides through your company. You could also explore creating a health-care-related business. All three industries are solid and in high demand both in Mauritius and internationally. Oil and oil-based products are employed in a variety of industries, including transportation and industry. In Mauritius, business is booming and profitable.

IsMauritius good for business?

Mauritius is a highly developed and successful country with an Internet café where you may set up PCs and other devices with a high-speed internet connection. Even if some people rely on their laptops and cellphones for online services, farming is becoming increasingly simple to maintain and cost-effective as technology advances. Chicken rearing for meat and eggs, snails, fruit processing, flower exports, cattle for meat and milk, and vegetable processing are all viable businesses to pursue. Tutoring is becoming more popular around the world every day, and you may cash in on it as a lucrative business opportunity.

Business-Friendly Policies and Government Initiatives;

The Mauritius government, particularly the Ministry of Investment, Trade and Industry (MITI), has established a number of business-friendly laws and programmes to attract entrepreneurs to start enterprises or relocate existing operations. The MITI also supports a number of organisations that assist entrepreneurs in establishing new enterprises, registering and operating them, expanding international trade, exporting, importing, or selling their products locally, hiring local or international personnel, and so on. Setting a shop in Mauritius has a number of significant advantages for enterprises. The government has made it simple for non-residents and foreigners to start and run enterprises in the country by providing tax breaks and payroll exemptions. Internationally, there are no minimum capital requirements; they can export, import, or sell their products locally; they can engage local or foreign personnel; and so on. Mauritius is a highly developed and successful country with an Internet café where you may set up PCs and other devices with a high-speed internet connection. Even if some people rely on their laptops and cellphones for online services, farming is becoming increasingly simple to maintain and cost-effective as technology advances. Chicken rearing for meat and eggs, snails, fruit processing, flower exports, cattle for meat and milk, and vegetable processing are all viable businesses to pursue. Tutoring is becoming more popular around the world every day, and you may cash in on it as a lucrative business opportunity. etc. These organisations also provide assistance to existing firms, such as free legal advice on how to comply with various rules and regulations, money for capital expenditures such as technology upgrades or machinery acquisitions, and advice on how to scale up operations by increasing production.

7 Industrial Infrastructure Mauritius

Plastics and food goods are two examples. International shipping is associated with offshore financial activity. Mauritius is at a critical juncture in its development. Manufacturing and the larger industrial sector must be crucial to the national aim of maintaining high income status by 2030, which necessitates a creative, well-resourced, and well monitored industrial strategy. According to international trade data, Mauritius has performed admirably in terms of products exports and imports. In reality, India was the leading importer of goods from Mauritius in 2013-14, followed by France and South Africa, respectively. In addition, India was placed first as the top exporter of goods to Mauritius, followed by South Africa and France. This obviously demonstrates that India is a viable option for starting a business in Mauritius. Sugar, textiles, clothes, footwear, and tourism are the principal industries. The island is noted for producing some of the world's most valuable gemstones, such as rubies (Mogok) and sapphires (Chamarel). Sugar cane processing accounts for roughly 12% of industrial activity; textiles, cement, and other products are also manufactured.

What are the steps for Starting a Business Mauritius?

Mauritius has exhibited an increase in international trade figures. To start a business in Mauritius, you must first figure out what items or services your potential clients would want or want. You can either perform market research to see how many people are interested in your product, find businesses that already provide your idea and see how they do, or use secondary data such as government data on high-growing sectors and GDP growth estimates. Choose one of these three alternatives once you've determined what type of business is most likely to succeed: Starting your own business may appear to be a simple undertaking, but it requires perseverance and drive. Take note of these helpful hints for launching your own company in Mauritius. Make sure you're aware of any legislation that may apply to your company: It's critical to be informed of government rules that may have an impact on how you conduct your company.

Certain firms, for example, require special licences or permits before they can open their doors; if this applies to you, make sure you apply as soon as possible. Mauritius is slowly but steadily becoming a component of corporate expansion initiatives in a variety of industries. If you're considering extending your company's activities overseas and have considered Mauritius, you should reconsider because Mauritius is no longer only a tourist destination. In fact, starting a business in Mauritius has become more pro-business over time. 1) Decide on a name and register it with the appropriate government institutions.

(2)Open a bank account and submit an application for an employer identification number (EIN). If necessary, purchase insurance to protect your company's assets and personnel.

(3)Obtain the necessary licences and permits from local authorities in order to operate your business, such as health department licences and construction permits.

(4) Promote your company.

(5) Market your company

Market size of Mauritius

Mauritius' economy has already displayed signs of environmental stress in areas such as water, fisheries, and forests. This study analyses significant socio-economic areas that may be responsible for environmental degradation and, as a result, natural resource depletion.

The global economy can be defined as the sum of all activities that occur both within and between countries. The Mauritian economy is divided into several sectors, each with its own industrial production, labour market, financial market, resources, and environment.

Textiles, tourism, financial and business services, information and communication technology, seafood processing, real estate development, energy, and education/training are the most important. The Mauritius government (GoM) is stressing innovation as a foundation for long-term success. Mauritius claims to be the only island in the Indian Ocean. Mauritius. Make sure you're aware of any legislation that may apply to your company: It's critical to be informed of government rules that may have an impact on how you conduct your company. Certain firms, for example, require special licences or permits before they can open their doors; if this applies to you, make sure you apply as soon as possible. Mauritius is slowly but steadily becoming a component of corporate expansion initiatives in a variety of industries. If you're considering extending your company's activities overseas and have considered Mauritius,

you should reconsider because Mauritius is no longer only a tourist destination. In fact, starting a business in Mauritius has become more pro-business over time. 1) Decide on a name and register it with the appropriate government institutions.

(2) Open a bank account and submit an application for an employer identification number (EIN). If necessary, purchase insurance to protect your company's assets and personnel.

(3) Obtain the necessary licences and permits from local authorities in order to operate your business, such as health department licences and construction permits.

(4) Promote your company.

(5) Market your company

Industrial growth

Mauritius' economy is diverse, with services, industry, and tourism each accounting for roughly one-third of GDP. Since its independence in 1968, the country has witnessed remarkable economic growth. It had a GDP per capita (PPP) of $13,846 in 2011 and a life expectancy of 74 years. Mauritius is at a critical juncture in its development. Manufacturing and the larger industrial sector must be crucial to the national aim of maintaining high income status by 2030, which necessitates a creative, well-resourced, and well monitored industrial strategy. Mauritius' economy, which is largely open and free-market, is based on tourism and textiles. Agriculture generates less than 3% of total output and employment. For local consumption, sugar, citrus, tea, rice, corn, and other food crops are farmed. Mauritian items were exported to a variety of countries. Japan, Malaysia, and France are three of the most populous countries in the world. By promoting foreign investment, the government hopes to develop high-value-added industries (such as medicines). Mauritius has no natural resources that can be exploited, thus it must rely on imported petroleum products to supply its energy needs. Recent underwater oil deposit finds may pave the way for the creation of a local petroleum sector in the future years. High growth rates (5–6% per year) have recently been attained. This result was achieved after three decades of dedicated work by successive governments.

Mauritius is a very beautiful country with many tourist attractions for everyone who chooses Mauritius as their finest business destination. Mauritius' GDP has been stable for a few years, with a mixed, strong, and developed economy — when it comes to financial services, Mauritius offers incredible business opportunities in a variety of sectors, including agro industries, logistics and distribution services, manufacturing and light engineering, seafood and aquaculture, IT & BPO, financial services, healthcare, medical travel, property development, hospitality, renewable energy, and the environment. Agriculture, tourism, real estate, and exports are the first three. Mauritius is a small island nation where the majority of goods are imported from all over the world. As a result, delivery services are always in high demand.Deliver larger products in order to make a profit. Everything you'll need for

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 11 of 54 | Total 539 projects in this category

« Previous Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 53 54 Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all

Sort by

E-Waste Recycling Plant
Electronic wastes, "e-waste", "e-scrap", or "Waste Electrical and Electronic Equipment" ("WEEE") is a description of surplus, obsolete, broken or discarded electrical or electronic devices. Technically, electronic "waste" is the component which is dumped or disposed or discarded rather than recycled, including residue from reuse and recycling operations. Because loads of surplus electronics are frequently coming led (good, recyclable, and non-recyclable), several public policy advocates apply the term "e-waste" broadly to all surplus electronics. Electronic Waste – or e-waste – is the term used to describe old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc. which have been disposed of by their original users. While there is no generally accepted definition of e-waste, in most cases, e-waste comprises of relatively expensive and essentially durable products used for data processing, telecommunications or entertainment in private households and businesses. The rising levels of e-waste generation in India have been a matter of concern in recent years. With more than 100 crore mobile phones in circulation, nearly 25 per cent end up in e-waste annually.“India has surely emerged as the second largest mobile market with 1.03 billion subscribers, but also the fifth largest producer of e-waste in the world, discarding roughly 18.5 lakh metric tonnes of electronic waste each year, with telecom equipment alone accounting for 12 per cent of the e-waste’’. The fastest growing sources of waste and is estimated to be increasing by 16-28 per cent every five years. Within each sector a complex set of heterogeneous secondary wastes is created. Although treatment requirements are complicated, the sources from any one sector possess many common characteristics. However, there exist huge variations in the nature of electronic wastes between sectors, and treatment regimes appropriate for one cannot be readily transferred to another. E-Waste or Electronic Waste broadly describes loosely discarded, surplus, broken, obsolete, electrical and electronic devices. E-Waste is an area of immediate and long-term concern as its unregulated accumulation and recycling can lead to major environmental degradation which will pose a major threat to human health. Revolution of IT, new and innovative technologies and globalization of economy have made new electronic products available and affordable. But on the other hand, it has also led to unrestrained resource consumption and E-Waste generation. Electronic waste (e-waste) typically includes discarded computer monitors, motherboards, mobile phones and chargers, compact discs, headphones, television sets, air conditioners and refrigerators. According to the Global E-Waste Monitor 2017, India generates about 2 million tonnes (MT) of e-waste annually and ranks fifth among e-waste producing countries, after the US, China, Japan and Germany. In 2016-17, India treated only 0.036 MT of its e-waste. About 95 per cent of India’s e-waste is recycled in the informal sector and in a crude manner. Only 20 per cent of global e-waste is recycled. The market in Asia-Pacific has been categorized as China, Japan, India, and the rest of Asia-Pacific. The market in Asia-Pacific is expected to register the highest CAGR of 15.25% during the forecast period. Japan is expected to be a leading country-level market and is expected to register a 12.75% CAGR. India is expected to be the fastest-growing country-level market, expected to register the highest CAGR over the next few years. This is due to the growing population in the region. Also, growing awareness of e-waste recycling and government initiatives are the major factors for the growth of the market. India is emerging as one of the world's major electronic waste generators, posing grave concerns to public health and environment alike.Industry body Assocham, said India’s ‘production’ of e-waste is likely to increase by nearly three times, from the existing 18 lakh metric tons (MT) to 52 lakh MT) per annum by 2020 at a compound annual growth rate (CAGR) of about 30%.The Global Electronic Waste Recycling Market is expected to expand at 13.03% CAGR to reach a market value of 39,498.81 Million in 2024. A mere 1.5% of India's total e-waste gets recycled due to poor infrastructure, legislation and framework which leads to a waste of diminishing natural resources, irreparable damage of environment and health of the people working in industry. Over 95% of e-waste generated is managed by the unorganized sector and scrap dealers in this market, dismantle the disposed products instead of recycling it. Few Indian major players are as under E-ParisaraaPvt Ltd Attero India Pvt Ltd, E-waste Recyclers India, Eco Recycling Limited (ECORECO), Hi-Tech Recycling India Pvt. Ltd., Ultrust Solutions Pvt. Ltd.,
Plant capacity: Aluminium : 3 MT / day Mild Steel: 2 MT / day Shredded PCB: 15.00 MT / day	Plant & machinery: Rs 88 lakhs
Working capital: -	T.C.I: Cost of Project: Rs 533 lakhs
Return: 29.00%	Break even: 59.00%
Add to Inquiry Basket

Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol)
The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Cefalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins. It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth. Cefalexin can be used in those who have mild or moderate allergies to penicillin. However, it is not recommended in those with severe penicillin allergies. Ampicillin is an antibiotic used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it is not useful for the treatment of viral infections. Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint. Paracetamol is generally safe at recommended doses. The recommended maximum daily dose for an adult is three to four grams. Higher doses may lead to toxicity, including liver failure. Serious skin rashes may rarely occur. It appears to be safe during pregnancy and when breastfeeding. In those with liver disease, it may still be used, but in lower doses. It is classified as a mild analgesic. It does not have significant anti-inflammatory activity. How it works is not entirely clear. Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug (NSAID) class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used by mouth or intravenously. It typically begins working within an hour India's reliance on pharma ingredient imports has risen over the past few decades due to the higher cost of domestic production, with the price gap reaching as much as 20%-30%, particularly for energy-intensive fermentation-based ingredients used in anti-infectives. Import dependence is more than 90% for some life-saving drugs, including penicillin and ciprofloxacin. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. Asia Pacific is expected to be the fastest-growing market over the forecast period. Owing to the availability of affordable labor, major companies in the market are setting up API manufacturing plants in developing countries such as China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd.
Plant capacity: Paracetamol: 500 Kgs / day Cephalexin: 500 Kgs / day Ampicillin Trihydrate: 500 Kgs / day Ibuprofen: 500 Kgs / day	Plant & machinery: Rs 347 lakhs
Working capital: -	T.C.I: Cost of Project: Rs 1656 lakhs
Return: 36.00%	Break even: 52.00%
Add to Inquiry Basket

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.
API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Related Projects:- Active Pharma Ingredients (api) The API form that is used in a formulation is often the most thermodynamically stable crystalline form. As such, the phenomenon of hydrogen bonding in combination with there being many functional groups on the API usually results in the available crystalline form being a hydrate. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumonia, Streptococcus pyogenic, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. Market Outlook The production-linked incentive scheme - which accounts for INR0.9 billion of planned outlay - offers an incentive of up to 20% of sales for fermentation based products and up to 10% for chemical synthesis-based products for the next eight to nine years. This should help to bridge the price gap and make domestic production more competitive. The government has also allocated USD0.4 billion under the capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks. We believe this will aid the investment decisions of Indian pharma companies, particularly in the current environment where the focus in on conserving cash. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Higher Growth in the APAC Active Pharmaceutical Ingredients Market Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe. Books:- BOOKS & DATABASES Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. Related Videos:- Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Videos:- Manufacturing Business Ideas in Pharmaceutical Industry Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. Related Projects:- Startup Opportunities in Active Pharma Ingredients The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. Market Research Reports:- India Active Pharmaceutical Ingredient (API) The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Market Research:- Market Research Reports Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Projects: - Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol) Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Related Projects: - Active Pharma Ingredients (API) Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Projects: - Project Reports & Profiles For More Details, Click Here: - Key players Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. For More Details, Click Here: - https://bit.ly/32McBPb Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -	Plant & machinery: -
Working capital: -	T.C.I: -
Return: 1.00%	Break even: N/A
Add to Inquiry Basket

Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API),
Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API), Are you searching for manufacturing business ideas? If you have sizeable money to invest and a more risk-taking ability, starting a business is a good decision. Product manufacturers can generate new value, minimize costs, and increase operational stability by focusing and prioritizing on four broad areas: production, product design, value recovery, and supply-chain management. Thinking about stepping into manufacturing industry business, you need to consider the option of starting on a limited size production. Starting with the making of essential components of the various industries. Once you set up things well, you could choose to start an industry and gradually become the giant of the industry. Projects:- Project Reports & Profiles Get ready and quickly go through these top business ideas that are the best options available with high return on investment. Choose any of these high net profit margin ideas if you want to start a venture in the manufacturing industry. Becoming an entrepreneur easier than ever before—technology is shrinking the world, opening markets, and making it possible for many people to strike out on their own in the field of their dreams. An entrepreneur who starts his own business can break free from this actuarial perspective and redefine the value he brings to the market. Books:- BOOKS & DATABASES Dairy Farming & Dairy Products (Milk, Butter, Ghee & Paneer) Dairy farming may be a class of agriculture for long-term production of milk, which is processed for eventual sale of a dairy product. Dairying is a very important source of subsidiary income to small/marginal farmers and agricultural laborers. India derives nearly 33% of the gross Domestic population from agriculture and has 66% of economically active population, engaged in agriculture. The share of livestock product is estimated at 21% of total agriculture sector. Milk production alone involves over 70 million producers, each raising one or two cows/buffaloes primarily for milk production. Additionally to exploit, the manure from animals provides an honest source of organic matter for improving soil fertility and crop yields. The gobar gas from the dung is used as fuel for domestic purposes as also for running engines for drawing water from well. In Hinduism; cow urine features a special significance as a drink. Sprinkling of cow urine is said to possess a spiritual cleansing effect furthermore. Gomutra isn't a toxic industrial waste material. 95% of its water, 2.5% consists of urea, and therefore the remaining 2.5% may be a mixture of minerals, salts, hormones and enzymes. Related Projects:- Milk & Dairy Products The global dairy products market is expected to grow at a CAGR of 5.2% from 2019 to reach $645.8 billion by 2025. Dairy is defined as a business enterprise that deals with the processing and harvesting of animal milk for human consumption. Some of the common milch animals include cow, goat, buffalo, camel and sheep. The milk obtained from these animals can be consumed directly and processed into ice cream, cheese, paneer, butter, ghee, condensed milk and yogurt. These products offer various nutrients such as calcium, proteins, zinc, magnesium, and vitamin D and B12. With widespread demand for dairy products and their proactive function in the global food industry, dairy plays a crucial role in the growth of the economies worldwide. Over the years, the dairy industry has witnessed improvements in product safety through specialization, modernization and consolidation. Moreover, advancements in global trade have also influenced the profitability of dairy farms. Related Books:- Milk Processing, Dairy & Dairy Products, Poultry Industries As of 2018, India is the leading milk producing country in the world, accounting for ~19% of the global market share. The milk processing industry in India is expected to expand at a compound annual growth rate (CAGR) of ~14.8% between FY 2018 and FY 2023, and will reach INR 2,458.7 Bn in FY 2023. Groundnut Oil Groundnut oil may be a vegetable oil derived from groundnuts. It’s also called groundnut oil. The oil features a strong peanut flavor and aroma. It’s often utilized in American, Chinese, South Asian and Southeast Asian cuisine, both for general cooking, and within the case of roasted oil, for added flavor. Unrefined groundnut oil features a smoke point of 320°F/160°C and is employed as a flavor ant for dishes like sesame oil. Groundnut haulms are nutritious and widely used for feeding livestock. The groundnut oil consists of mixed glycerides, and contain a high proportion of unsaturated fatty acids, especially Oleic (50-56%) and Linoleic (18-30%). Related Projects: - Edible Oils Projects In India, groundnut is cultivated in 5.8 million hectares. Gujarat is that the highest producer of groundnut oil in India. Groundnut seed contains 50-55% of the oil. It’s one among the most effective oil seeds to extract oil from. Increasing use of groundnut oil in cosmetics are getting to be one altogether the primary drivers of the peanut oil market. The abrasive, volatizing, and cleansing properties of hot-pressed groundnut oil and its derivatives are boosting its application in BPC product and cosmetics, such as moisturizers and skin cleansers. Growing popularity of blended oil are getting to be one altogether the critical groundnut oil market trends. The utilization of cheap alternatives, similar to oil in blended oil makes it more affordable than conventional oil. These advantages can boost the popularity of homogenized groundnut oil and consequently fuel the growth of the groundnut oil market. Related Books:- Market Research Report on Edible Oils in India However, the high production cost of peanut oil is a major factor expected to restraint growth of the target market in the near future. In addition, high consumption of peanut oil results in various side effects in human health which is one of the major factors expected to hamper growth of the target market to a certain extent. Global peanut oil market is set to witness a steady CAGR of 4.25% in the forecast period of 2019- 2026. Nicotine from Tobacco Waste Nicotine may be a natural product of tobacco, occurring within the leaves of nicotiana tabacum during a range of 0.5 to 7.5% counting on variety. Nicotine is additionally found within the leaves of nicotiana rustica, in amounts of 2–14%; in Duboisia hopwoodii and in Asclepias syriaca. Nicotine may be a widely used stimulant and potent par sympathomimetic alkaloid that's naturally produced within the nightshade family of plants. It’s used for smoking cessation to alleviate withdrawal symptoms. Nicotine may be a widely used stimulant and potent para sympathomimetic alkaloid that's naturally produced within the nightshade family of plants. It’s used for smoking cessation to relieve withdrawal symptoms. Related Projects:- Tobacco, Pan Masala, Khaini, Gutkha, Supari, Zarda, Mouth Freshener The India Tobacco Board has authorized a 2020 Traditional FCV crop size of 90 million kilos. However, crop size is estimated at 96 million kilos. A grade spread consisting of 20 million kilos of bright, 25 million kilos of the medium, and 51 million kilos of low style tobacco. 90% of the crop is already harvested. The average market price is USD 2.10 for this year. Indian Tobacco Board has authorized an NLS 2020 crop size of 46 million kilos. However, a crop size 42 million kgs is anticipated which was transplanted in 17,000 hectares and 90% of the crop has been harvested. The average market price is expected to be USD 2.30 for this year. Related Books:- Agriculture, Agro Based, Bakery, Wood, Ice Cream, Corn, Tobacco And Tobacco Products IV Fluids (BFS Technology) Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to guard patients from injury, and there are variety of various types available to be used. Many companies manufacture packaged intravenous fluids, also as products which may be mixed with sterile water to prepare a solution for intravenous administration. Fluids are given when someone's body fluid volume falls. There are variety of things which may cause a drop by fluid volume. Vomiting and diarrhea are a classic example, which is why people are encouraged to drink fluids once they are sick, to stay their fluid volume stable. Another cause is blood loss, which causes problems both because people lose blood products, and because they experience a loss in fluid volume. Electrolyte levels within the blood also can become unstable as a result of rapid changes in fluid volume, during which case intravenous fluids are often used to restore the balance. Related Projects:- IV Fluids, I.V. solutions, Intravenous fluids The primary costumers for these manufacturing units are Hospitals, Clinics, Dialysis centers, Home care settings. The global Intravenous Fluid market size was valued at US$ 8,372.0 million in 2019 and is expected to witness a CAGR of 6.1% over the forecast period (2019 – 2027). The basic function of I.V. fluids is to replenish body fluids. It can also be used in the treatment of electrolyte metabolism, especially in severe cases, therapy of acid-base in balances, the volume substitution and volume replacement in surgery of accident victims suffering blood loss. It can be used as parenteral nutrition for severally ill and post-operative patients. Related Books:- BOOKS & DATABASES Disposable Nitrile Gloves Nitrile gloves are a kind of disposable gloves made up of synthetic rubber, this suggests there's no risk of latex allergies. They the foremost popular gloves type in our range and offer superior strength, dexterity and resistance to oils and aqueous chemicals as compared to vinyl or latex. For these reasons, they're often utilized in the medical, laboratory and manufacturing industries. Nitrile gloves are an excellent compromise between latex and vinyl. Our Blue Nitrile gloves offer protection from bodily fluids providing a barrier that forestalls infection, cross-infection or cross-contamination. Tests revealed that Nitrile gloves are three times more puncture-resistant than rubber gloves. Related Projects:- Disposable Products and Projects from Paper The Indian market for medical gloves is still evolving. While the global market is growing at a compound annual growth rate (CAGR) of two per cent, the Indian market is at seven per cent growth. Every day there is a new hospital or nursing home popping up in India, so the demand for medical gloves is expected to increase. Medical tourism is also driving the growth of this product category in our country. The market size therefore only for gloves in India is Rs 300 crore. In view of all this, there is a good scope to initiate small-scale rubber gloves manufacturing unit. The Global Rubber Gloves market is expected to grow at a CAGR of 8.5% between 2014 and 2022. The factors such as rising healthcare expenditure, increasing health threats and increasing hygiene awareness and healthcare regulations are driving the market growth. Related Video:- Production of Disposable Nitrile Gloves Nitrile gloves are preferred over latex gloves because they resist chemicals, including certain disinfectants such as chlorine. There is a high rate of allergies to latex and contact allergic dermatitis among health workers. Non powdered gloves are preferred to powdered gloves. Toothpaste Toothpaste may be a paste or gel to be used with a toothbrush to maintain and improve oral health and aesthetics. Since their introduction several thousand years ago, toothpaste formulations have evolved considerably - from suspensions of crushed egg shells or ashes to complex formulations with often over 20 ingredients. Among these are often compounds to combat dental caries, gum disease, malodor, calculus, erosion and dentin hypersensitivity. Furthermore, toothpastes contain abrasives to wash and whiten teeth, flavors for the aim of breathe freshening and dyes for better visual appeal. Effective toothpastes are people who are formulated for maximum bioavailability of their actives. This, however, are often challenging as compromises will need to be made when several different actives are formulated in one phase. Related Projects:- Hygiene Products, Essential Personal Hygiene Products The global toothpaste market is projected to grow at a CAGR of 6.1% during the forecast period. The toothpaste market was valued at USD 26.09 billion in 2018, and it is projected to reach USD 36.98 billion by 2024. Increasing dental problems among children and adults, due to poor eating habits, and the rise in popularity for herbal oral care products are the factors primarily driving the global toothpaste market. Related Video:- Startup Business Opportunities in Toothpaste The rapidly changing lifestyle, improper diet, including sugar-rich diets, and therefore the increased consumption of alcohol and tobacco have made oral health one among the main public health problems in almost every a part of the planet. The impact of oral diseases on people's everyday lives is subtle and pervasive, influencing food habits, sleep, rest, social roles, and almost every phase of the day. Collectively, oral diseases and disorders create substantial pain and suffering. Because of this, consumers across the planet have started paying immense attention to maintaining their oral health, which has led to a rise within the sales of toothpaste across the world. Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol) The Active Pharmaceutical Ingredient (API) is that the part of any drug that produces the intended effects. Some drugs, like combination therapies, have multiple active ingredients to treat different symptoms or act in several ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to chop costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Related Projects:- Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing India is that the seventh largest country within the world and has the second highest population. It a parliamentary democratic variety of government and has abundant natural resources and sufficient oil reserves. The country features a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one among the most important recipients of FDI within the world. Asia Pacific is predicted to be the fastest-growing market over the forecast period. Because of the supply of affordable labor, major companies within the market are setting up API manufacturing plants in developing countries like China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. Related Book:- India Active Pharmaceutical Ingredient (API) Market The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Tags:- #dairy #dairyfarming #DairyProducts #dairyindustry #GroundnutOil #Nicotine #tobaccowaste #IVFLUIDS #disposablenitrilegloves #disposablegloves #toothpaste #toothpastebusiness #hygieneindustry #ToothpasteIndustry #ToothpasteMarket #ToothpasteProject #activepharmaingredients #API #apimanufacturing #Apiproduction #ActivePharmaceuticalIngredient #pharmaceuticalindustry #apimarket #businessconsultant #businessfeasibilityreport #DetailedProjectReport #EntrepreneurIndia #startupideas #NPCS
Plant capacity: -	Plant & machinery: -
Working capital: -	T.C.I: -
Return: 1.00%	Break even: N/A
Add to Inquiry Basket

E-Waste Recycling Plant
Electronic wastes, "e-waste", "e-scrap", or "Waste Electrical and Electronic Equipment" ("WEEE") is a description of surplus, obsolete, broken or discarded electrical or electronic devices. Technically, electronic "waste" is the component which is dumped or disposed or discarded rather than recycled, including residue from reuse and recycling operations. Because loads of surplus electronics are frequently coming led (good, recyclable, and non-recyclable), several public policy advocates apply the term "e-waste" broadly to all surplus electronics. Electronic Waste – or e-waste – is the term used to describe old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc. which have been disposed of by their original users. While there is no generally accepted definition of e-waste, in most cases, e-waste comprises of relatively expensive and essentially durable products used for data processing, telecommunications or entertainment in private households and businesses. The rising levels of e-waste generation in India have been a matter of concern in recent years. With more than 100 crore mobile phones in circulation, nearly 25 per cent end up in e-waste annually. “India has surely emerged as the second largest mobile market with 1.03 billion subscribers, but also the fifth largest producer of e-waste in the world, discarding roughly 18.5 lakh metric tonnes of electronic waste each year, with telecom equipment alone accounting for 12 per cent of the e-waste’’. The fastest growing sources of waste and is estimated to be increasing by 16-28 per cent every five years. Within each sector a complex set of heterogeneous secondary wastes is created. Although treatment requirements are complicated, the sources from any one sector possess many common characteristics. However, there exist huge variations in the nature of electronic wastes between sectors, and treatment regimes appropriate for one cannot be readily transferred to another. The ‘Electronic Waste Management in India,’ conducted to mark World Environment Day, said as Indians become richer and spend more on electronic items and appliances, computer equipment accounts for almost 70% of e-waste material, followed by telecommunication equipment (12%), electrical equipment (8%) and medical equipment (7%). Other equipment, including household e-crap account for the remaining 4%. India is emerging as one of the world's major electronic waste generators, posing grave concerns to public health and environment alike. Industry body Assocham, said India’s ‘production’ of e-waste is likely to increase by nearly three times, from the existing 18 lakh metric tons (MT) to 52 lakh MT) per annum by 2020 at a compound annual growth rate (CAGR) of about 30%.The Global Electronic Waste Recycling Market is expected to expand at 13.03% CAGR to reach a market value of 39,498.81 Million in 2024. A mere 1.5% of India's total e-waste gets recycled due to poor infrastructure, legislation and framework which leads to a waste of diminishing natural resources, irreparable damage of environment and health of the people working in industry. Over 95% of e-waste generated is managed by the unorganized sector and scrap dealers in this market, dismantle the disposed products instead of recycling it. The market in Asia-Pacific has been categorized as China, Japan, India, and the rest of Asia-Pacific. The market in Asia-Pacific is expected to register the highest CAGR of 15.25% during the forecast period. Japan is expected to be a leading country-level market and is expected to register a 12.75% CAGR. India is expected to be the fastest-growing country-level market, expected to register the highest CAGR over the next few years. This is due to the growing population in the region. Also, growing awareness of e-waste recycling and government initiatives are the major factors for the growth of the market.
Plant capacity: Plastic Granules: 470 Kgs / Day Glass Scrap: 353 Kgs / Day Copper Scrap: 294 Kgs / Day Precious Metals (Nickel, Tin & Zinc): 60.00 Kgs / Day Gold : 0.0192 Kgs / Day Silver: 0.0384 Kgs / Day Palladium: 0.0010 Kgs / Da	Plant & machinery: Rs 107 lakhs
Working capital: -	T.C.I: Cost of Project : Rs 336 lakhs
Return: 28.00%	Break even: 58.00%
Add to Inquiry Basket

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac
Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing the prevalence of therapeutic and chronic diseases i.e., diabetes, cancer etc. with rising population in this region. According to WHO, around 65% of all cancer deaths occur in developing countries and the number of global cancer deaths is projected to increase by 45 percent from 2007 to 2030 with from 7.9 million to 11.5 million deaths influenced by rise in consumption of tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol in this region. The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Sanofi India Ltd. Piramal Enterprises Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
Plant capacity: Azithromycin: 500 Kgs / Day Cefixime: 500 Kgs / Day Telmisartan: 50 Kgs / Day Diclofenac Sodium: 500 Kgs / Day Aceclofenac: 500 Kgs / Day	Plant & machinery: Rs 155 lakhs
Working capital: -	T.C.I: Cost of Project : Rs 729 lakhs
Return: 31.00%	Break even: 61.00%
Add to Inquiry Basket

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac
Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing the prevalence of therapeutic and chronic diseases i.e., diabetes, cancer etc. with rising population in this region. According to WHO, around 65% of all cancer deaths occur in developing countries and the number of global cancer deaths is projected to increase by 45 percent from 2007 to 2030 with from 7.9 million to 11.5 million deaths influenced by rise in consumption of tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol in this region. The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Sanofi India Ltd. Piramal Enterprises Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
Plant capacity: Azithromycin: 500 Kgs / Day Cefixime: 500 Kgs / Day Telmisartan: 50 Kgs / Day Diclofenac Sodium: 500 Kgs / Day Aceclofenac: 500 Kgs / Day	Plant & machinery: Rs 155 lakhs
Working capital: -	T.C.I: Cost of Project : Rs 729 lakhs
Return: 31.00%	Break even: 61.00%
Add to Inquiry Basket

Plastic Waste Recycling Plant
Waste is now a global problem, and one that must be addressed in order to solve the world's resource and energy challenges. Plastics are made from limited resources such as petroleum, and huge advances are being made in the development of technologies to recycle plastic waste among other resources. Mechanical recycling methods to make plastic products and feedstock recycling methods that use plastic as a raw material in the chemical industry have been widely adopted, and awareness has also grown recently of the importance of Thermal recycling as a means of using plastics as an energy source to conserve petroleum resources. Plastic, in many applications, can do a better job at a lower cost than other materials. Each plastic should be selected on the basis of its properties. Thus, each plastic is not an answer to all problems. Here in this project report we have considered Ten Plastic materials, out of that major four plastic materials have LDPE, HDPE, PP, Pet bottles and Derlin. Industrial applications like various components for Textiles, Transport Containers, Storage Containers, Bottle crates, Galvanized components for Automobiles and plumbing, woven sacks for packing a variety of products like fertilizers, powdered chemicals, pesticides, etc. sheet lining of Tanks/Vessels for chemicals. Plastic recycling refers to a process that is performed either mechanically or chemically to recover plastic waste from discarded items for production of reusable plastic. The global plastic recycling market has been gaining a steady momentum over the past few years due to the growing awareness about carbon emissions and the need to reduce them. Citing this reason, the report states that the global plastic recycling market, which was valued at US$31.5 bn in 2015 is expected to reach a figure of US$56.8 Bn by 2024. During the forecast period of 2016 and 2024, the global market is expected to progress at a CAGR of 6.9%. The market is witnessing growth due to a growing preference for recycled plastics over virgin plastics as a result of severe pollution caused by the disposal of used plastics in oceans and the scarcity of landfill areas in many countries. Factors such as increasing use of recycled plastics in many new applications in the packaging, automotive and the electrical & electronics industry and many favorable initiatives promoting the use of recycled plastics worldwide offer lucrative opportunities for the growth of the recycled plastics market. Higher cost of recycled plastics. Stringent competition with virgin plastics in terms of performance is a major factor restraining the growth of the market. The ban on import of certain waste plastic scraps to China and irregular collection of the waste plastics for its reprocessing are some of the factors challenging the growth of the global recycled plastics market globally. Entrepreneurs who invest in this project will be successful. Few Indian major players are as under Garden Polymers Pvt. Ltd. Himalayan Packaging Inds. Pvt. Ltd. Kkalpana Industries (India) Ltd. South Asian Petrochem Ltd. Renaissance Corporation Ltd. Jain Plastics & Chemicals Ltd
Plant capacity: Recycled PP Granules: 578 Kgs / Day Recycled LDPE Granules : 720 Kgs / Day Recycled HDPE Granules: 727 Kgs / Day Recycled Delrin Granules: 475 Kgs / Day Recycled PET Granules: 2,500 Kgs / Day	Plant & machinery: Rs 144 lakhs
Working capital: -	T.C.I: Cost of Project : Rs 380 lakhs
Return: 26.00%	Break even: 68.00%
Add to Inquiry Basket

Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API).
Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API). Opportunities for Entrepreneurs to Start Own Industry. The active pharmaceutical ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Related Project: - Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Acecloflenac Active Pharmaceutical Ingredient (API) is the portion of drug that generates intentional effects. APIs are biologically and chemically active constituents of medicines with direct effect in mitigation, prevention, cure and treatment of diseases. Some of the medicines like combination therapies have many active ingredients to treat diverse symptoms or perform in numerous ways. Active Pharmaceutical Ingredient has active ingredient that is contained in medicine. For illustration, an active ingredient to reduce pain is incorporated in a painkiller. A slight amount of the active ingredient has result thus only small part of the active ingredient is confined in medicine. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredients Market Dynamics The growing cases of chronic diseases are one of the leading causes of hospitalization, and a majority of the patients with these conditions may need re-admission in hospitals due to infection leading to other chronic diseases. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults in the US dealt with at least one type of cardiovascular disease in 2017. Besides, CDC has also stated that out of the total annual healthcare expenditure, i.e., USD 27 trillion, 86% is for the people with chronic health conditions in the US. Some of the prime factors spurring the growth of the market are increasing occurrences of cardiovascular, oncology, lifestyle and diabetes diseases, intensifying number of diagnostic centers and hospitals and escalating elderly population in emerging countries. Furthermore, cumulative healthcare spending, growing disease responsiveness and education are propelling the growth of the market. Related Projects: - Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing With advancements in healthcare infrastructure, healthcare spending has increased over time. This augmenting focus on healthcare spending positively influences the market for active pharmaceutical ingredients. The high adoption rate of generic drugs in developed and developing economies is fueling the growth of the market. Another positive impact comes from the high demand for specialty medicines which is anticipated to escalate the spending in the pharmaceutical sector. Developed nations are expected to exhibit faster growth in these spending as compared to the developing economies on the back of factors such as the presence of adequate manufacturing units, transparent pricing, and higher spending power. Specialty medicines a trend in the active pharmaceutical ingredients market A higher generic adoption rate in developed countries that ranges from 27% to 32% is driving global medicine spending and aiding greater access to improved, lifesaving healthcare services. The adoption of branded generic drugs is predicted to be higher in emerging economies such as China and India and generic drugs accounted for nearly 80% of the total drugs sold by value in these fast-growing nations in 2016. Rising use of specialty medicines is anticipated to grow the pharmaceutical spending worldwide with quicker growth in richer, developed nations as compared to their emerging counterparts. This is primarily because the former have adequate manufacturing units, a higher spending power, and greater emphasis on transparent pricing by assessing measuring effects on the population. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Active pharmaceutical ingredient (API), is the term that is used to refer to the biologically active component of a drug (e.g. tablet, capsule). A drug is usually composed of several components. The API represents the primary ingredient. Other ingredients are commonly known as "excipients. Sometimes a drug can contain several APIs and its effect on a patient depends on the dosage prescribed and can vary from person to person. In combination therapies, two or more than two active ingredients are used to treat different symptoms in different ways. Stringent quality control is a mandate when it comes to the manufacturing of drugs as the API represents the main component considered while making the prescription. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs. Key Players:- Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. Tags: - #APIBusiness #apimanufacturing #Apiproduction #APImarket #APIProject #ApiStartup #APIindustry #Activepharmaingredients #pharmaingredients #IndianPharma, #medicineingredients #CoronavirusBusiness #COVID2019 #Activepharmaingredientbusinessplan #APIbusinessplan #APIbusinessidea #startupAPIbusiness #Activepharmaingredientmanufacturing #APIproduction #API #Azithromycin #Cefixime #Telmisartan #Diclofenacsodium #Acecloflenac #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #entrepreneurindia #startupbusiness #startupbusinessideas #howtostartbusiness #InvestInStartups #Plan4Business #StartupProject #ProjectReport #startupplan #BusinessKaiseshurukare #BusinessProjectReport
Plant capacity: -	Plant & machinery: -
Working capital: -	T.C.I: -
Return: 1.00%	Break even: N/A
Add to Inquiry Basket

Manufacturing of Ciprofloxacin Hydrochloride (CIPRO) - Active Pharma Ingredient
Manufacturing of Ciprofloxacin Hydrochloride (CIPRO) - Active Pharma Ingredient. Investment Opportunity for Startups and Entrepreneurs. Ciprofloxacin is an antibiotic agent in the fluoroquinolone class used to treat bacterial infections such as urinary tract infections and pneumonia. Ciprofloxacin is FDA approved for the treatment of urinary tract infections, sexually transmitted infections (gonorrhea and cancroid), skin, bone and joint infections, prostatitis, typhoid fever, gastrointestinal infections, lower respiratory tract infections, anthrax, plague, and salmonellosis. Related Projects: - Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing Uses and Applications Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent. This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. Mycoplasma contamination is a major problem in cell culture in biomedical and biopharmaceutical research, with rates near 15-30%. While there is no method for visual confirmation of mycoplasma, contamination has serious effects on key characteristics and functions of cells, thus compromising any research done. Cipro (ciprofloxacin hydrochloride) is the standard antibiotic for rapid and efficient decontamination. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks CIPRO is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Ciprofloxacin (Cetraxal, Ciloxan, and Cipro) is an inexpensive drug used to treat certain bacterial infections. It is more popular than comparable drugs. Application Urogenital Infections Respiratory Tract Infections Gastrointestinal Infections Typhoid Bone and Joint Infections Skin and Soft Tissue Infections Sepsis and Other Systemic Infections Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Government Initiatives • Some of the initiatives taken by the Government to promote the pharmaceutical sector in India are as follows: • India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically by 2023. • In November 2019, the Cabinet approved extension/renewal of extant Pharmaceuticals Purchase Policy (PPP) with the same terms and conditions while adding one additional product namely, Alcoholic Hand Disinfectant (AHD) to the existing list of 103 medicines till the final closure/strategic disinvestment of Pharma CPSUs. • Under Budget 2020-21, Rs 65,012 crore (US$ 9.30 billion) has been allocated to the Ministry of Health and Family Welfare is. The Government has allocated Rs 34,115 crore (US$ 4.88 billion) towards the National Health Mission under which rural and urban people will get benefited. • Rs 6,400 crore (US$ 915.72 million) has been allocated to health insurance scheme Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). • As per Economic Survey 2019-20, Government expenditure (as a percentage of GDP) increased to 1.6 per cent in FY20 from 1.2 per cent in FY15 on health. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates • The National Health Protection Scheme is the largest Government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh (US$ 7,723.2) per family per year for secondary and tertiary care hospitalisation. The programme was announced in Union Budget 2018-19. • The Government of India is planning to set up an electronic platform to regulate online pharmacies under a new policy to stop any misuse due to easy availability. • Government of India unveiled 'Pharma Vision 2020' to make India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investment. • India has imposed a provisional anti-dumping duty on imports of Ciprofloxacin Hydrochloride from China on the grounds that it was hurting domestic industry, following an investigation of the Directorate General of Trade Remedies (DGTR). • The department of revenue issued a notification to the effect on September 2, imposing a duty ranging between $0.94 and $3.29 per kg coming from China. • Ciprofloxacin Hydrochloride is used to treat different types of bacterial infections and certain types of diarrhea. The DGTR had initiated the investigation in January this year. Related Videos: - Industrial, Medical and Specialty Gases Manufacturing Project Ideas Market Outlook The India ciprofloxacin market is segmented based on composition, source, and form, route of administration, distribution channel, application, end user, company and region. Based on route of administration, the market can be categorized into oral, ophthalmic, optic, and intravenous and others. The intravenous segment is expected to witness significant growth through FY2026. This can be ascribed to the use of this route of administration for the drugs which are not absorbed after consumption through oral route. Additionally, large quantities of drug can be administered using this route of drug administration with 100% bioavailability. The Global Ciprofloxacin Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027. Related Project:- Ciprofloxacin Hydrochloride Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biological, Ayush and herbal products and surgical. The remaining of the active pharmaceutical ingredient of ciprofloxacin is being dispersed in another combination product and specifically utilize in the urinary tract antibiotic only. Thereby anticipated to lure the new market players in the ciprofloxacin market. The higher incidence of skin and immunological disorder is anticipated to offer a steady revenue generation opportunity in the ciprofloxacin market. Increase awareness about safe drug utilization, however increase in adverse drug reaction awareness and stringent government impositions have narrowed the growth path for global Ciprofloxacin market in North America. Furthermore in East Asia region considerably higher market growth rate is expected due to higher utilization of ciprofloxacin in renal infection in the region. Thereby anticipated to increase the revenue generation in the Ciprofloxacin market. Related Projects: - Chemicals (Organic, Inorganic, Industrial) Projects The bulk drugs segment continues to be the highest revenue generating segment for the Indian pharma industry. It accounts for production worth Rs 120 bn and contributes about 36% of the total pharma exports. India produces 400 bulk drugs through its 1,300 licensed bulk drug units that cater to most of the domestic bulk drug requirements. Related Projects: - Active Pharma Ingredients(API) Key Players:- ? Aarti Drugs Ltd. ? Aurobindo Pharma Ltd. ? Cipla Ltd. ? Indoco Remedies Ltd. ? Kores (India) Ltd. ? Mylan Pharmaceuticals Pvt. Ltd. ? Neuland Laboratories Ltd. ? S S Organics Ltd ? Smruthi Organics Ltd. ? Sreepathi Pharmaceuticals Ltd. ? Sterling Basic Organics Ltd. ? Sun Pharma Laboratories Ltd. ? Sun Pharma Medisales Pvt. Ltd. ? Wockhardt Ltd. Tags:- #CiprofloxacinHydrochloride #Ciprofloxacin #CiprofloxacinBusinessPlan #activepharmaceuticalingrediants #activepharmaingredient #Pharmaceutical #pharmaindustry #APIManufacturing #APIProduction #APImarket #APIBusiness #APIbusinessplan #startupAPIbusiness #CIPRO #startyourbusiness #investmentopportunity #covidbusiness #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #bussinessplanshub #Startupbusiness4you #StartupBusinessPlan #startupinvestment #startup #ChemicalIndustry
Plant capacity: -	Plant & machinery: -
Working capital: -	T.C.I: -
Return: 1.00%	Break even: N/A
Add to Inquiry Basket

Information

One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
One Crore is equivalent to ten million (10,000,000)
T.C.I is Total Capital Investment
We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.
Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 11 of 54 | Total 539 projects in this category

« Previous Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 53 54 Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top

Google Search

Search

Already a Member ?

Best Business Opportunities in Mauritius, Africa - Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

E-Waste Recycling Plant

Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol)

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.

Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API),

E-Waste Recycling Plant

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac

Plastic Waste Recycling Plant

Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API).

Manufacturing of Ciprofloxacin Hydrochloride (CIPRO) - Active Pharma Ingredient

About NIIR PROJECT CONSULTANCY SERVICES